Genmab — Juli 2019
-
Copenhagen, Denmark; July 16, 2019 Genmab A/S (Nasdaq Copenhagen: GEN)
announced today that worldwide net sales of DARZALEX (daratumumab) as
reported by Johnson & Johnson were USD 774 million in the second quarter of
2019 compared to USD 511 million in the second quarter of 2018, an increase
of approximately 51%. The 2019 second quarter net sales were USD 369
million in the U.S. and USD 405 million in the rest of the world. -
According to Johnson & Johnson, sales in the second quarter of 2019
included a one-time adjustment outside the U.S. related to the completion
of pricing and reimbursement discussions in certain European countries,
which positively impacted this worldwide operational growth by 16
percentage points.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind